白三烯受体拮抗剂对咳嗽变异性哮喘的作用
[Effect of leukotriene receptor antagonist on cough variant asthma].
作者信息
He Zhi-min, Guo Yu-biao, Xie Can-mao
机构信息
Department of Internal Medicine, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
出版信息
Nan Fang Yi Ke Da Xue Xue Bao. 2009 Apr;29(4):694-6.
OBJECTIVE
To study the curative effect of leukotriene receptor antagonist on cough variant asthma (CVA).
METHODS
Sixty-four CVA patients received treatment with bricany and montelukas and 68 control patients had bricany treatment for 4 weeks. The recurrence rate was observed in the two groups during the follow-up for 6 months.
RESULTS
The remission time of two groups were 2.5-/+3.6 and 5.3-/+3.8 days in acute phase, respectively, showing a significant difference between them (P<0.05). The recurrence rate of the two groups within 6 months were 20.09% and 40.87%, respectively, showing also significantly differences (P<0.05).
CONCLUSION
Leukotriene receptor antagonist and bricany can effectively control CVA and significantly lower the short-term recurrence rate of CVA.
目的
研究白三烯受体拮抗剂对咳嗽变异性哮喘（CVA）的疗效。
方法
64例CVA患者接受布地奈德和孟鲁司特治疗，68例对照患者接受布地奈德治疗4周。随访6个月观察两组的复发率。
结果
两组急性期缓解时间分别为2.5±3.6天和5.3±3.8天，差异有统计学意义（P<0.05）。两组6个月内复发率分别为20.09%和40.87%，差异也有统计学意义（P<0.05）。
结论
白三烯受体拮抗剂和布地奈德可有效控制CVA，并显著降低CVA的短期复发率。
Zotero 插件